UPDATED: South Africa sidelines AstraZeneca's vaccine after it failed to protect against new variant in a study, raising global alarms
South Africa is slamming the brakes on the rollout of AstraZeneca and Oxford University’s Covid-19 vaccine after data showed it did not protect against mild-to-moderate cases caused by the B.1.351 variant, which is now widespread in the country.
Professor Salim Abdool Karim, one of South Africa’s leading Covid-19 experts, told reporters in a briefing on Sunday that the country is putting a temporary hold on the administration of one million AstraZeneca vaccines that have already been delivered.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.